Sort
21,453 grants matching “tuberculosis”
Development of a highly-multiplexed CRISPR-based TB drug susceptibility test
$791,030Yingda Linda Xie · Rutgers Biomedical And Health Sciences · R01 · FY2024 · AI
ULTRASHORT-COURSE TREATMENT OF DRUG-SENSITIVE AND DRUG-RESISTANT TUBERCULOSIS VIA INHALATION AND NANOTHERAPEUTIC DELIVERY OF NOVEL DRUG REGIMEN
$790,997University Of California, Los Angeles · · FY2020 · Defense Health Agency
Structure, function, and regulation of the bacterial transcription cycle
$790,955Seth A Darst · Rockefeller University · R35 · FY2016 · GM
A Preclinical Program for Targeting Mycobacterium tuberculosis KasA
$790,771Joel Stephen Freundlich · Rutgers Biomedical And Health Sciences · R01 · FY2024 · AI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection
$790,569John Zapata Metcalfe · University Of California, San Francisco · R01 · FY2018 · AI
TB Vaccine Development in Nonhuman Primate Model
$790,437John L Vandeberg · Texas Biomedical Research Institute · R01 · FY2008 · AI
Mtb and HIV/SIV antigen peptide signatures as blood biomarkers to detect early infection to active disease in young children and NHP
$790,427Christopher J Lyon · Tulane University Of Louisiana · R01 · FY2021 · HD
Post-Tuberculosis Lung Disease in Youth with and without HIV Globally
$790,320Leslie Anne Enane · Indiana University Indianapolis · R01 · FY2025 · AI
Exploration, conservation, and development of marine bi*
$790,175Mark E Hay · Georgia Institute Of Technology · U01 · FY2007 · TW
Exploration, conservation, and development of marine bi*
$790,175Mark E Hay · Georgia Institute Of Technology · U01 · FY2008 · TW
Transcriptomics of Tuberculosis Latency and Reactivation in Primates
$790,087Deepak Kaushal · Tulane University Of Louisiana · R01 · FY2010 · HL
Mississippi Tuberculosis Prevention, Control, and Elimination and Laboratory Cooperative Agreement
$789,638Sennett D. · Mississippi State Department Of Health · U52 · FY2015 · PS
Lesion-centric imaging and PK-PD of pyrazinamide for TB/HIV co-infection
$789,586Veronique Dartois · Rbhs-New Jersey Medical School · R01 · FY2014 · AI
A multi-disciplinary approach to the identification of host metabolic determinan
$789,511Megan Murray · Brigham And Women'S Hospital · U19 · FY2021 · AI
Characterization of the cellular and molecular bases of inborn errors of immunity
$789,400Luigi Notarangelo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Molecular Analysis of Host Immune Response in Leprosy
$789,331Robert L Modlin · University Of California Los Angeles · R01 · FY2025 · AI
Lesion-centric imaging and PK-PD of pyrazinamide for TB/HIV co-infection
$788,890Veronique Dartois · Rbhs-New Jersey Medical School · R01 · FY2015 · AI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM IN AIDS
$788,853Donna Mildvan · Beth Israel Medical Ctr (New York) · U01 · FY2007 · AI
Characteristics and protective efficacy of human antibodies against M. tuberculosis
$788,818Jacqueline Michele Achkar · Albert Einstein College Of Medicine · R01 · FY2019 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT
$788,606Greduvel Duran-Guzman · Puerto Rico Department Of Health · U52 · FY2012 · PS
Human Genetic determinants of HBV recovery
$788,585David L Thomas · Johns Hopkins University · R01 · FY2020 · AI
C type Lectin Pathway Regulates Macrophage Immune Metabolism in Mtb-Infected Lung
$788,478Janice J Endsley · University Of Texas Med Br Galveston · R01 · FY2025 · HL
De facto monotherapy during multidrug TB treatment and emergence of resistance
$788,371Veronique Dartois · Rbhs-New Jersey Medical School · R01 · FY2017 · AI
Preventing TB with intravenous BCG in SIV-infected macaques
$788,364Charles A. Scanga · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AI
A Multidisciplinary Approach to Understanding TB Latency and Reactivation
$788,317Petros C Karakousis · Johns Hopkins University · R01 · FY2011 · HL